Researchers from King’s College London have succeeded in developing a blood test that can help choose the best treatment for depression patients – a big improvement over the current trial-and-error approach.
Depression doesn’t seem to be a particularly popular indication for biotechs, unlike other nervous systems diseases that reached significant milestones in the last year. Moreover, one of the few programmes for the disease had a recent Phase II failure.
Now, researchers at King’s College London have made a breakthrough in the field – not in a novel therapy but for a more effective diagnosis.
Published in the The International Journal of Neuropsychopharmacology, their work shows how a blood test can accurately and reliably predict whether depressed patients will respond to common antidepressants.
The blood test is based on previous scientific findings of how high levels of inflammation are associated with poor response to antidepressants. The test analyses two biomarkers of inflammation that can be present in the blood –